Zebrafish embryotoxicity test for developmental (neuro)toxicity: Demo case of an integrated screening approach system using anti-epileptic drugs

被引:37
作者
van Woudenberg, Anna Beker [1 ]
Snel, Cor [2 ]
Rijkmans, Eke [1 ]
de Groot, Didima [1 ]
Bouma, Marga [1 ]
Hermsen, Sanne [3 ]
Piersma, Aldert [3 ]
Menke, Aswin [2 ]
Wolterbeek, Andre [1 ]
机构
[1] TNO, Res Grp Risk Anal Prod Dev RAPID, NL-3700 AJ Zeist, Netherlands
[2] TNO Triskel BV, Zeist, Netherlands
[3] Natl Inst Publ Hlth & Environm RIVM, Ctr Hlth Protect, Bilthoven, Netherlands
关键词
Zebrafish embryotoxicity test (ZET); Developmental (neuro)toxicity; Antiepileptic drugs; Integrated test strategy; Histopathology; Kinetics; Behavior; Gene expression; IN-UTERO EXPOSURE; LOCOMOTOR-ACTIVITY; VALPROIC ACID; REPRODUCTIVE TOXICANTS; HISTONE DEACETYLASE; FETAL EXPOSURE; TOXICITY; EMBRYO; PREGNANCY; EPILEPSY;
D O I
10.1016/j.reprotox.2014.07.082
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
To improve the predictability of the zebrafish embryotoxicity test (ZET) for developmental (neuro)toxicity screening, we used a multiple-endpoints strategy, including morphology, motor activity (MA), histopathology and kinetics. The model compounds used were antiepileptic drugs (AEDs): valproic acid (VPA), carbamazepine (CBZ), ethosuximide (ETH) and levetiracetam (LEV). For VPA, histopathology was the most sensitive parameter, showing effects already at 60 mu M. For CBZ, morphology and MA were the most sensitive parameters, showing effects at 180 mu M. For ETH, all endpoints showed similar sensitivity (6.6 mM), whereas MA was the most sensitive parameter for LEV (40 mM). Inclusion of kinetics did not alter the absolute ranking of the compounds, but the relative potency was changed considerably. Taking all together, this demo-case study showed that inclusion of multiple-endpoints in ZET may increase the sensitivity of the assay, contribute to the elucidation of the mode of toxic action and to a better definition of the applicability domain of ZET. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:101 / 116
页数:16
相关论文
共 58 条
[1]  
[Anonymous], 2007, GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRAF GUIDE LAB USE ZEBRA
[2]   Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery [J].
Barros, T. P. ;
Alderton, W. K. ;
Reynolds, H. M. ;
Roach, A. G. ;
Berghmans, S. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (07) :1400-1413
[3]   Zebrafish offer the potential for a primary screen to identify a wide variety of potential anticonvulsants [J].
Berghmans, Stephane ;
Hunt, Julia ;
Roach, Alan ;
Goldsmith, Paul .
EPILEPSY RESEARCH, 2007, 75 (01) :18-28
[4]   Development of a Zebrafish Embryo Teratogenicity Assay and Quantitative Prediction Model [J].
Brannen, Kimberly C. ;
Panzica-Kelly, Julieta M. ;
Danberry, Tracy L. ;
Augustine-Rauch, Karen A. .
BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2010, 89 (01) :66-77
[5]   Neural progenitor cells as models for high-throughput screens of developmental neurotoxicity: State of the science [J].
Breier, Joseph M. ;
Gassmann, Kathrin ;
Kayser, Reinier ;
Stegeman, Hanneke ;
De Groot, Didima ;
Fritsche, Ellen ;
Shafer, Timothy J. .
NEUROTOXICOLOGY AND TERATOLOGY, 2010, 32 (01) :4-15
[6]  
Chuang C-M, 2012, PLOS ONE, V7
[7]   Locomotor activity assay in zebrafish larvae: Influence of age, strain and ethanol [J].
de Esch, Celine ;
van der Linde, Herma ;
Slieker, Roderick ;
Willemsen, Rob ;
Wolterbeek, Andre ;
Woutersen, Ruud ;
De Groot, Didima .
NEUROTOXICOLOGY AND TERATOLOGY, 2012, 34 (04) :425-433
[8]   Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth [J].
Dean, JCS ;
Hailey, H ;
Moore, SJ ;
Lloyd, DJ ;
Turnpenny, PD ;
Little, J .
JOURNAL OF MEDICAL GENETICS, 2002, 39 (04) :251-259
[9]  
Diekmann H., 2013, Drug Discov. Today Dis. Models, V10, pe31, DOI [10.1016/j.ddmod.2012.02.005, DOI 10.1016/J.DDMOD.2012.02.005]
[10]  
DIN, 2002, 38415T6 DIN, P27